Nuvation Bio Inc. (NUVB) is a publicly traded Healthcare sector company. As of May 20, 2026, NUVB trades at $4.45 with a market cap of $1.47B and a P/E ratio of -10.73. NUVB moved +6.49% today. Year to date, NUVB is -47.50%; over the trailing twelve months it is +107.83%. Its 52-week range spans $1.54 to $9.75. Analyst consensus is strong buy with an average price target of $13.17. Rallies surfaces NUVB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
NUVB financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. NUVB recently traded at $4.45. Market cap is $1.47B. P/E ratio is -10.73. Revenue is $143.05M.
| Metric | Value |
|---|---|
| Price | $4.45 |
| Market Cap | $1.47B |
| P/E Ratio | -10.73 |
| EPS | $-0.42 |
| Dividend Yield | 0.00% |
| 52-Week High | $9.75 |
| 52-Week Low | $1.54 |
| Volume | 4.47M |
| Avg Volume | 0 |
| Revenue (TTM) | $143.05M |
| Net Income | $-145.99M |
| Gross Margin | 0.00% |
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $62.90M | $-204.63M | $-0.60 |
| 2024 | $7.87M | $-567.94M | $-2.11 |
| 2023 | $0 | $-75.80M | $-0.35 |
| 2022 | $0 | $-104.20M | $-0.48 |
7 analysts cover NUVB: 0 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $13.17.